Joseph Jorizzo to Double-Blind Method
This is a "connection" page, showing publications Joseph Jorizzo has written about Double-Blind Method.
Connection Strength
0.328
-
Jorizzo JL, Markowitz O, Lebwohl MG, Bourcier M, Kulp J, Meng TC, Levy S. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol. 2010 Sep; 9(9):1101-8.
Score: 0.086
-
Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, McRae S, Fielder S, Lee JH. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007 Aug; 57(2):265-8.
Score: 0.069
-
Savin R, Jorizzo J. The safety and efficacy of sertaconazole nitrate cream 2% for tinea pedis. Cutis. 2006 Oct; 78(4):268-74.
Score: 0.066
-
Jorizzo J, Weiss J, Furst K, VandePol C, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004 Jul; 140(7):813-6.
Score: 0.056
-
Gold LS, Cruz A, Eichenfield L, Tan J, Jorizzo J, Kerrouche N, Dhuin JC. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis. 2010 Feb; 85(2):94-104.
Score: 0.021
-
Parish LC, Jorizzo JL, Breton JJ, Hirman JW, Scangarella NE, Shawar RM, White SM. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol. 2006 Dec; 55(6):1003-13.
Score: 0.016
-
Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004 May; 50(5):714-21.
Score: 0.014